Connect with us

Health

CARB-X funds Phico to develop new intravenous engineered bacteriophage drug – The Pharma Letter

Global non-profit partnership CARB-X is funding privately-held UK company Phico Therapeutics to develop a new intravenous engineered bacteriophage drug to treat

Published

on

Global non-profit partnership CARB-X is funding privately-held UK company Phico Therapeutics to develop…To continue reading The Pharma Letter please login,  subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space.
Or, if you’re only interested in reading the content about a specific topic (M&A, coronavirus/COVID-19, pricing, reimbursement and access, outsourcing, CRO…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Diaverum acquires booknowmed.com – News-Medical.net
Article feature image
Could the AstraZeneca vaccine cause Guillain-Barré syndrome? We don’t know yet — but there’s minimal cause for concern – The Conversation AU